1. Scrip

Jazz Poised To Hold Onto Strong Sleep Disorder Position

 
• By Leah Samuel and Jessica Merrill

Jazz detailed Phase III data on a next-generation narcolepsy drug that could extend the life of its successful Xyrem franchise. The launch of Sunosi also is underway.  

Jazz Pharmaceuticals PLC detailed positive Phase III data on a next-generation narcolepsy drug that could extend the company's solid position in the space at the World Sleep meeting on 26 September. The company is hoping to file a new drug application for the product, JZP-258, by the end of the year, after meeting with the US Food and Drug Administration.

JZP-258 is positioned as a safer version of Jazz's blockbuster Xyrem (sodium oxybate). It is being developed for the treatment of cataplexy and excessive daytime sleepiness in adults with narcolepsy, the same indication for which Xyrem is approved

More from Neurological

More from Therapy Areas

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.